Based on the above results, CIP2A acts as a prognostic marker in patients with wild-type KRAS metastatic colorectal cancer following colorectal liver metastasectomy, because the mutational activation of KRAS weakens CIP2A regulation on cell survival. The gene discussed is CIP2A; the disease is metastatic colorectal cancer.